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• Fulvestrant monotherapy and the combination therapy of everolimus and exemestane are two options among newer therapies approved for use in HR+/HER2-advanced breast cancer patients • There is limited evidence comparing treatment outcomes of everolimus-based therapy (EVE) and fulvestrant monotherapy (FUL) in postmenopausal HR+/HER2-mBC patients in the real-world setting
STUDY OBJECTIVES
• To assess the real-world comparative effectiveness of EVE vs. FUL as measured by progressionfree survival (PFS) in postmenopausal women with HR+/HER2-mBC in community-based oncology practices
DATA
Retrospective review of medical records
• A nationwide sample of medical charts of HR+/HER2-mBC patients in the US was collected from a panel of community-based oncologists and hematologists • Physicians were asked to identify patients who met the selection criteria and randomly select up to 10 medical charts from eligible patients • Stratified sampling was used and quotas were implemented to ensure sufficient sample size in each treatment group (EVE, FUL) by line of therapy (first-line, second-line, third-line and above) • All data collected in the chart review were individually non-identifiable. The study was approved and granted exemption by the New England Institutional Review Board as a retrospective, non-interventional study of non-identifiable data
Patient Inclusion Criteria
• Postmenopausal women with HR+/HER2-mBC, either as a de novo diagnosis or as a result of recurrence of a previous breast cancer with evidence of distant disease • Initiated a new treatment in any line in the mBC setting between July 1st, 2012 and April 15th, 2013
(the first treatment initiated during this time frame was defined as the index treatment) • Experienced recurrence or progression on or after a non-steroidal aromatase inhibitor (NSAI) in an adjuvant or metastatic setting before initiating the index treatment • Was not enrolled in any clinical trial • Did not have a history of a non-breast cancer primary malignancy (with the exception of non-melanoma skin cancer and carcinoma in situ of the cervix uteri) within three years prior to the first mBC diagnosis date • Had accessible medical records from their first mBC diagnosis to the last follow-up with their physicians
Study Groups
• EVE group: patients who received everolimus monotherapy, or combination therapy of everolimus with another endocrine or chemotherapy agent as index treatment • FUL group: patients who received fulvestrant monotherapy as index treatment • In both groups, patients who received any everolimus-based or fulvestrant-based therapies before their index treatment were excluded from the study sample
STUDY MEASURES AND STATISTICAL ANALYSIS Baseline characteristics
• Patient characteristics were assessed at the initiation of index treatment: age, race, insurance type, disease status (de novo, recurrent with adjuvant endocrine therapy, recurrent without adjuvant endocrine therapy), line of therapy, time from initiation of last adjuvant endocrine therapy to the mBC diagnosis, adjusted Charlson Comorbidity Index (CCI) (excluding score of 2 for metastatic cancer), Eastern Cooperative Oncology Group (ECOG) performance status, number and sites of metastases, physician-classified tumor volume, and prior chemotherapy in the mBC setting • Compared using Wilcoxon rank-sum tests for continuous variables and Chi-square tests for categorical variables between EVE and FUL groups
Outcome
• PFS: Time from initiation of index treatment to progression or death, whichever occurred first. Progression was determined by the physician based on radiographic evidence or tests, physical exams, symptoms, or other methods. Patients who did not progress or die were censored at the last follow-up date • Compared using Kaplan-Meier (KM) curves and log-rank tests • Hazard ratios (HRs) for PFS were estimated using univariable and multivariable Cox proportional hazards models. The multivariable model adjusted for line of therapy, age, adjusted CCI, sites of metastases, ECOG score at initiation of index treatment; disease status, race, and insurance plan type at the mBC diagnosis; prior chemotherapy in the mBC setting, and duration from initiation of last adjuvant endocrine therapy to the mBC diagnosis -A second set of regressions included an interaction term between line of therapy and treatment group to compare EVE and FUL across lines of therapy -Statistical significance was assessed at the 0.05 level
RESULTS
Baseline Characteristics (Table 1) • A total of 192 and 156 patients received EVE and FUL as their index treatment respectively • At index treatment initiation, patients treated with EVE were less likely to have bone metastases, but were more likely to have liver or visceral metastases compared to patients treated with FUL • Patients treated with EVE were more likely to have received prior chemotherapy in the mBC setting before index treatment initiation, and also had shorter duration from initiation of last adjuvant ET to mBC diagnosis compared to patients treated with FUL 
Comparisons of PFS
• In the unadjusted analyses, the PFS difference was marginally non-significant between EVE and FUL ( Figure 1 Months from initiation of index treatment
Log-rank P = 0.05
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LIMITATIONS
• As a retrospective chart review the current study may be subject to errors or data omissions in medical charts. However, these would be expected to affect all patients to a similar extent and are unlikely to bias the direction of the comparative conclusions • Although the multivariable analysis adjusted for a number of patient characteristics that are commonly recorded in medical charts and known to be prognostic, unobserved confounding factors and selection bias could exist between the EVE and FUL groups • Only a well-conducted randomized controlled trial can avoid confounding due to unobserved factors
CONCLUSION
• This retrospective chart review study described progression-free survival of postmenopausal women with HR+/HER2-mBC who received everolimus-based therapy or fulvestrant monotherapy after progression on NSAI, and conducted exploratory comparative analyses between the two groups
• Our results suggested that patients who received everolimus-based therapy tended to have more aggressive mBC at baseline than those treated with fulvestrant monotherapy at initiation of therapy
• After adjusting for baseline characteristics, everolimus-based therapy was associated with significantly longer PFS compared to fulvestrant monotherapy, particularly in second-, third-, and later-lines of treatment
